554a0d8581716f391d56b3bc89466a86.jpg

Markforged CEO Shai Terem: “Real growth is coming to AM” Decision Makers

After going public and trading on NYSE since July 2021, Markforged has been releasing detailed data on its performance. For over a decade, all 3D printing stocks have suffered from long periods of decreasing value interrupted by short bursts of very rapid growth. Markforged’s stock has been no different; and yet the company’s growth has been solid, regular and organic, with a “strong balance sheet and a track record of execution to our industry”, as Markforged CEO Shai Terem put it during the latest analyst call on Q1 2022 results when the company reported revenues of $21.9 million and 8.6% YoY growth. 3dpbm had the opportunity to speak with Mr. Terem about Markforged’s latest results, ongoing growth strategy and medium to long-term goals.

Humabiologics partners with Fisher Scientific Bioprinting

Humabiologics Partners with Fisher Scientific Bioprinting

Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers, and Fisher Scientific, a global leader in life sciences, are partnering to serve researchers in academia and industry who are working on regenerative medicine research.